4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $29.8750.

Several equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth about $46,000. Millennium Management LLC boosted its stake in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after buying an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth about $39,000. American Century Companies Inc. boosted its stake in shares of 4D Molecular Therapeutics by 11.5% during the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after buying an additional 5,026 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of 4D Molecular Therapeutics by 11.7% during the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after buying an additional 2,284 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $8.83 on Wednesday. The stock has a 50-day simple moving average of $9.48 and a 200-day simple moving average of $9.18. The stock has a market cap of $461.63 million, a P/E ratio of -3.44 and a beta of 2.75. 4D Molecular Therapeutics has a 1 year low of $3.68 and a 1 year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, equities research analysts predict that 4D Molecular Therapeutics will post -3.8 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.